Matthew Beare
Family Medicine · Bakersfield, CANPI 1326400052
Payments from drug & device makers
Across 257 payments — averaging $382.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$68K
- AbbVie$23K
- Braeburn Inc.$6K
- Viiv Healthcare Company$357
- Indivior Inc.$191
- Merck$158
- plus $414 from 13 others
What the payments were for
- Consulting fees$4,7605%
- Speaking & faculty fees$76,52378%
- Travel & lodging$10,08810%
- Food & beverage$6,8657%
- Education$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 122 | $68,331 |
| AbbVie | 61 | $23,106 |
| Braeburn Inc. | 22 | $5,706 |
| Viiv Healthcare Company | 16 | $357 |
| Indivior Inc. | 9 | $191 |
| Merck | 7 | $158 |
| Smith+Nephew | 2 | $54 |
| Alkermes, Inc. | 2 | $48 |
| E.r. Squibb & Sons, L.L.C. | 2 | $43 |
| Dynavax Technologies Corporation | 2 | $39 |
| Novo Nordisk | 2 | $37 |
| Lilly USA, LLC | 2 | $32 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Exact Sciences | 1 | $27 |
| Hologic Sales And Service, LLC | 1 | $25 |
| Pfizer | 1 | $20 |
| AstraZeneca | 1 | $20 |
| Bayer | 1 | $18 |
| GSK | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$98,264 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 140 | $25,241 |
| EliquisApixaban | 13 | $7,215 |
| Spiriva HandihalerTiotropium Bromide | 12 | $6,343 |
| Buprenorphine Hcl | 28 | $1,877 |
| Dextroamphetamine Sulfate | 12 | $922 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 28 | $783 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 27 | $610 |
| Gabapentin | 31 | $578 |
| Ibuprofen | 54 | $388 |
| Bupropion Hcl SrBupropion Hcl | 25 | $386 |
| Quetiapine Fumarate | 17 | $284 |
| Methadone Hcl | 14 | $195 |
| Lisinopril | 38 | $185 |
| Omeprazole | 23 | $178 |
| Buspirone Hcl | 18 | $171 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $20 | $7,21513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.
Other family medicine in Bakersfield
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.